The Board reviewed with the CEO and EMT the key aspects from the CEO monthly report and supporting papers, and the Board Strategic Scorecard Report, which had been circulated prior to the meeting.
The Board discussed a number of senior appointments noting that
- Damien McCallion has taken on the role of Chief Operations Officer (COO) on an interim basis and the recruitment process for the COO post has commenced with the hope of securing a suitable candidate by year-end.
- John Ward as Interim CTTO, reporting directly to the CEO and Puneet Sukreja who has taking up the role of Interim CISO, reporting directly to the CTTO. The CEO advised the Board of currently undergoing a recruitment process to fill these roles on a permanent basis by year-end.
- Eileen Whelan has taken on the role as Interim National Director of Vaccination, Testing & Tracing Programmes. The CEO updated the Board in relation to meetings he attended since the last Board meeting. A Cabinet Committee meeting was held on 9 June 2022, to discuss and outline the current status in relation to HSE recruitment targets; waiting lists; emergency department’s current performance and the financial position. Further discussions on these items took place later in the board meeting. The CEO and a number of HSE officials attended the Joint Committee on Disability Matters and Children, Equality, Disability, Integration and Youth.
The CEO updated the Board regarding a meeting requested by the Minister for Health that HSE senior management had attended and advised that he wrote to the Minister outlining a number of concerns in relation to the organisation, attendees and discussion at the meeting.
The Board received an update in relation to the increased attendance at EDs and Covid numbers rising which is resulting in increased pressures noting this will need to be monitored and a judgement call on elective care may be required.
The CEO made reference to the report of HIQA’s inspection of the emergency department at University Hospital Limerick and informed the Board that the ND OPI team are currently working with UHL and HSE Midwest Community Healthcare to implement an action plan to include additional measures to improve patient streaming and hospital avoidance.
The CEO updated the Board on the response to the work ongoing in relation to the data breaches relating to the Cyberattack on the HSE in May 2021, noting that the Minister has written to the Attorney General on the matter. He informed the Board that a Steering Group has been established to propose an Action Plan to address the shortcomings in internal controls in the High Earners Review.
The Board then held a discussion focused on the following areas as addressed in the CEO Report:
Scorecard
The CEO presented the May 2022 Board Strategic Scorecard Report, as circulated prior to the meeting and noted that next months will be the half year report.
The Board discussed the ratings in relation to Key Programmes / Priorities, noting the following:
- The average rating of the 20 scorecards is 3.45, slightly down from last month’s scorecard average rating of 3.50. This is due to changes in the status of 3 scorecards: Prevention and Early Intervention, Infrastructure and Equipment and Enhancing Bed Capacity.
- Individual scorecards that show KPI progress ahead of target include Reform of Primary Care, Community and ECC and Technology and e-Health.
- As part of the engagement with the Department of Health and in line with reporting requirements, a supplemental Appendix to indicate alignment with the 2022 Letter of Determination has been included in the May 2022 Board Strategic Scorecard . Further improvements to highlight alignment are forthcoming.
Following the discussion the Board approved Board Strategic Scorecard Report for submission to the Minister. It was agreed that at the next Board meeting there would be a discussion of the process for determining Scorecard ratings and discussion on alignment of the programme/projects in the scorecard with the Corporate Risk Register.
Vaccination and Test and Trace
The Board discussed the progress with implementation on the future operating model for the Test and Trace Programme to transition from the current mass testing model to a surveillance led model with a GP clinical pathway. The Board noted that the transition plans for the Test & Trace Programme were presented to the Cabinet Sub-Committee where the strategy and overall approach were endorsed.
The Board discussed the surge response model arrangements in the Transition Plan, which will be required as part of the GP pathway in Winter 2022/2023, noting that the surge response will be triggered by an agreed set of criteria such as a surge in the disease in the community or pressure on GP capacity. NAS will provide the first line of response to a surge with up to 200 WTEs providing circa 25,000 per week, at pre agreed site locations around the country. If demand increases further, NAS can be supplemented by private providers to reach capacity of 45,000 swabs per week. In addition, there will be activation of additional laboratory capacity with key partners to accommodate the increased testing demands.
The Board emphasised the need to ensure for a strong communications strategy to manage any surge in the virus, and protect vulnerable people and ensure strong uptake in the Vaccination programme. The CEO confirmed a new Covid 19 Advisory Group has been established by the Department to advise Minister and Government on policy issues and communications.
He noted the Covid 19 Vaccination Programme will continue the administration of the second booster doses to over 65’s and over 12’s immunocompromised up to the end of June, and from July retained vaccination centres and participating pharmacies will continue to provide vaccinations for those choosing to take up their primary dose or secondary booster. Following questions from Board members, the details on the HSE website are to be reviewed to ensure appropriate information is provided. This is in relation to the vulnerable cohort who are to be vaccinated.
Finance
The CFO provided an overview to the Board on the April YTD figures. He noted that the revenue Income & Expenditure (I&E) financial position at the end of April 2022 shows a YTD deficit of €336m or 5.0%, more than 80% of this deficit caused by Covid-19 related costs. Capital I&E is showing a surplus of €39.4m, and Cash payments to end May are ahead of the cash profile by €335m.
Finance Q1 Forecast
The CFO informed the Board that indications from the Q1 Forecast show that there has been a concerning level of unfunded core costs year to date and this trend is currently predicted to continue through 2022. There is also a slower than expected fall off in Covid specific costs in community and hospital given the pattern of the disease over the last few months, and if unchecked will leave many of the services significantly exposed financially as we enter in the Estimates process for 2023. There is real pressure on general Government finances and significant competing demands from across the public sector, which is a very serious matter in this context.
The levels of unfunded costs that are being seen that are likely without action to be carried into 2023 are beyond what was previously expected. Elements of this, such as the re-emergence of strong price inflation pressures, are largely beyond our control but there is a need to take additional steps to ensure that every action to mitigate all unfunded costs is being taken.
Estimates and NSP 2023 Planning Process
The ND S&R presented to the Board the Estimates and the development of the National Service Plan, which outlined the proposed approach to the 2023 Planning Process, which was discussed previously by the Performance & Delivery Committee.
The Board discussed the following considerations which will need to be taken into consideration when finalising the 2023 estimate for expenditure:
- Ministerial priorities, not included in proposals, but could consume a potentially significant proportion of any new funding allocated.
- Significant Government financial pressure arising from additional demands on available public finances, including the need to respond to the War in Ukraine and rising inflationary pressures
- Residual open posts from the 2022 planning process, requiring approximately 6,000+ WTEs in 2023 for recruitment
- Impact of the roll-back of the Haddington Road Agreement and lost service delivery hours
- Rate of turnover of staff (including staff leaving due to emigration etc.) which in 2022 will create a further demand for fresh recruitment in order to stand still
- Lack of guarantee of the retention of Covid-specific funding (e.g. €200m access to care fund)
- Extent to which COVID-19 pandemic responses need to remain in place or be scaled down across hospital and community services
- Requirement to maintain an appropriate level of Test and Trace, Vaccination and Personal Protective Equipment in 2023.
It was agreed a further briefing will be provided at a future Board meeting and there will be on going engagement with the Performance and Delivery Committee.
Corporate Procurement Plan (CPP)
The CFO briefed the Board on the Corporate Procurement Plan (CPP) which set out the key actions required to support the HSE’s objectives to increase the level of procurement compliance, deliver value for money and support the delivery of the Government’s climate action plan.
The Board noted that the ARC reviewed the CPP 2022 at their meeting in June and provided feedback to the CFO, who advised that the Plan circulated to the Board has addressed that feedback. The Board supported the plan for publication.